HUP9904500A2 - Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia - Google Patents

Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Info

Publication number
HUP9904500A2
HUP9904500A2 HU9904500A HUP9904500A HUP9904500A2 HU P9904500 A2 HUP9904500 A2 HU P9904500A2 HU 9904500 A HU9904500 A HU 9904500A HU P9904500 A HUP9904500 A HU P9904500A HU P9904500 A2 HUP9904500 A2 HU P9904500A2
Authority
HU
Hungary
Prior art keywords
adenovirus
adenovirals
bicistron
dyslipoproteinemia
recombinant
Prior art date
Application number
HU9904500A
Other languages
Hungarian (hu)
Inventor
Patrick Benoit
Nicolas Duverger
Didier Rouy
Sandrine Seguret
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of HUP9904500A2 publication Critical patent/HUP9904500A2/en
Publication of HUP9904500A3 publication Critical patent/HUP9904500A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

A találmány tárgya egy hiányős rekőmbináns vírűs, előnyösen egyadenővírűs, azzal jellemezve, hőgy tartalmaz legalább kétnűkleinsavat, melyek a kőleszterin inverz transzpőrtjában szerepetjátszó elkülönült enzimet, fehérjét és/vagy kőfaktőrt kódőlnak, ahőlaz említett nűkleinsavak működőképesen kapcsőlódnak egy transzkripciósprőmóterhez, és azőkat egymástól egy IRES belső ribőszóma belépésihelyet kódőló szekvencia válaztja el. A tal tárgyát képezik még azilyen adenővírűsők előállítására alkalmas plazmid szerkezetek, azilyen plazmidőkkal vagy adenővírűsőkkal transzfőrmált sejtek, és azemlített adenővírűsőkat tartalmazó gyógyszerkészítmények is. ŕThe subject of the invention is a deficient recombinant virus, preferably a single-adenovirus, characterized by the fact that it contains at least two nucleic acids that encode a separate enzyme, protein and/or stone factor that plays a role in the inverse transport of cholesterol, in which said nucleic acids are functionally linked to a transcriptional promoter, and separated from each other by an IRES internal ribosome separated by a sequence that encodes an entry point. The subject matter of the invention also includes plasmid structures suitable for the production of such adenovirals, cells transformed with such plasmids or adenovirals, and pharmaceutical preparations containing the aforementioned adenovirals. ŕ

HU9904500A 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia HUP9904500A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (en) 1996-11-15 1996-11-15 BICISTRONIC RECOMBINANT VIRUSES USEFUL FOR THE TREATMENT OF DYSLIPOPROTEINEMIA-RELATED CONDITIONS

Publications (2)

Publication Number Publication Date
HUP9904500A2 true HUP9904500A2 (en) 2000-05-28
HUP9904500A3 HUP9904500A3 (en) 2002-01-28

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904500A HUP9904500A3 (en) 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Country Status (14)

Country Link
EP (1) EP0941355A1 (en)
JP (1) JP2001506488A (en)
KR (1) KR20000053320A (en)
AU (1) AU721654B2 (en)
BR (1) BR9712957A (en)
CA (1) CA2271437A1 (en)
CZ (1) CZ170399A3 (en)
FR (1) FR2755975B1 (en)
HU (1) HUP9904500A3 (en)
IL (1) IL129823A0 (en)
NO (1) NO992260D0 (en)
SK (1) SK63499A3 (en)
WO (1) WO1998022606A1 (en)
ZA (1) ZA9710271B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064392A2 (en) * 1998-03-16 2001-01-03 Introgen Therapeutics, Inc. Multigene vectors
AU7769800A (en) * 1999-08-10 2001-03-05 Develogen Ag Fur Entwicklungsbiologische Forschung Gene transfer combination vectors, method for the production and utilization thereof
FR2799472B1 (en) * 1999-10-07 2004-07-16 Aventis Pharma Sa PREPARATION OF RECOMBINANT ADENOVIRUSES AND ADENOVIRAL BANKS
AU2001247648B2 (en) * 2000-03-24 2006-03-30 Cold Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
EP1392504A4 (en) 2001-04-02 2008-03-05 Agilent Technologies Inc Sensor surfaces for detecting analytes
EP2741766B1 (en) * 2011-08-08 2015-10-07 Aptalis Pharma Limited Method for dissolution testing of solid compositions containing digestive enzymes
JP7316711B2 (en) * 2019-08-19 2023-07-28 ナンジン・ノベル・バイオテクノロジー・カンパニー・リミテッド A replicating oncolytic adenovirus that regulates lipid metabolism and its application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE213779T1 (en) * 1991-08-07 2002-03-15 W French Anderson INTERNAL RIBOSOME ENTRY SITES CONTAIN RETROVIRAL VECTORS
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (en) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Recombinant viruses and their use in gene therapy.
FR2722208B1 (en) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
EP0787200B1 (en) * 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
FR2731710B1 (en) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa RECOMBINANT VIRUSES EXPRESSING LECITHIN CHOLESTEROL ACYLTRANSFERASE AND USES IN GENE THERAPY

Also Published As

Publication number Publication date
FR2755975A1 (en) 1998-05-22
WO1998022606A1 (en) 1998-05-28
SK63499A3 (en) 2000-05-16
CZ170399A3 (en) 1999-08-11
KR20000053320A (en) 2000-08-25
AU5125298A (en) 1998-06-10
HUP9904500A3 (en) 2002-01-28
JP2001506488A (en) 2001-05-22
CA2271437A1 (en) 1998-05-28
EP0941355A1 (en) 1999-09-15
NO992260L (en) 1999-05-10
BR9712957A (en) 2000-02-01
IL129823A0 (en) 2000-02-29
FR2755975B1 (en) 1999-05-07
AU721654B2 (en) 2000-07-13
NO992260D0 (en) 1999-05-10
ZA9710271B (en) 1998-08-21

Similar Documents

Publication Publication Date Title
RU95115239A (en) Erythropoietin analog
AR018603A1 (en) A PEPTIDE, USEFUL FOR THE TREATMENT AND / OR PROFILAXIS OF ALZHEIMER'S DISEASE AND THE DOWN SYNDROME, PHARMACEUTICAL COMPOSITIONS AND VACCINES WHICH LOCATE, THE USE OF SUCH PEPTIDE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS OF DNA, SECTION A PLASMID OR VECTOR VI
HUP9901186A2 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
AU692163B2 (en) Retroviral vector for the transfer and expression of genes for therapeutical purposes in eucaryotic cells
AR006188A1 (en) "PHARMACEUTICAL COMPOSITION TO INHIBIT SERINPROTEASE ACTIVITY, IN VITRO METHOD TO INHIBIT SERINPROTEASE ACTIVITY AND METHOD TO PREPARE SUCH COMPOSITION".
EE04753B1 (en) Recombinant MVA virus and its use, isolated eukaryotic cell, method for producing recombinant hTyr protein and vaccine
RU95108217A (en) Defective recombinant adenovirus, cell strain, pharmaceutical composition
DK234890D0 (en) HUMANT C3B / C4B RECEPTOR TORQUE (CR1), NUCLEIC ACID SEQUENCES AND FRAGMENTS THEREOF, THEIR EXPRESSION, AND THE PROTEINS AND PEPTIDES CODED THEREOF
ATE228534T1 (en) HIGHER ORDER STRUCTURE AND BINDING OF PEPTIDE NUCLEIC ACIDS
DE69535035D1 (en) PREPARATIONS FOR THE ADMINISTRATION OF GENETIC MATERIAL
PT101297A (en) GLITARY MITOGENIC FACTORS, THEIR PREPARATION AND UTILIZATION
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
HUP9702377A2 (en) Self-enhancing, pharmacologically controllable expression systems
NO984415D0 (en) Peptides with antiproliferative properties
HUP9904500A2 (en) Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia
BR9811592A (en) Cytokinin oxidase
Toh et al. Identification of the nuclear factor HMG2 as an activator for DFF nuclease activity
ATE286139T1 (en) REPLICATION COMPETENT ANTI-TUMOR VECTORS
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
WO1999060110A3 (en) Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
EP0161007A3 (en) Retro - inverso c-terminal hexapeptide analogues of substance p
NO991995L (en) Nucleic acid and amino acid sequences related to Heliobacter pylori and vaccine compositions thereof
ATE332379T1 (en) HUMAN DNASE RESISTANT TO ACTIN INHIBITORS
NO984491D0 (en) SCF analog preparations and methods for their preparation
BR9812138A (en) Methods and compositions for therapies employing genes encoding secreted proteins such as interferon-beta